Oestrogen has neuroprotective effects and may reduce the risk of Alzheimer's disease

Expert Opinion on Biological Therapy

Volumn 2, Issue 6, 2002, Pages 647-657

  Eberling, Jamie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Memory; Neuroprotection; Oestrogen

Indexed keywords

ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE;

AGED; ALZHEIMER DISEASE; BRAIN FUNCTION; BRAIN RADIOGRAPHY; COGNITION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; MEMORY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ALZHEIMER DISEASE; BRAIN; COGNITION; ESTROGENS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MODELS, CHEMICAL; NEUROPROTECTIVE AGENTS; POSTMENOPAUSE; RISK;

ANIMALIA;

EID: 0036677230     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.6.647     Document Type: Review

References (129)

1. Estrogen replacement therapy in older women: Comparisons between Alzheimer's disease cases and nondemented control subjects
2. Estrogen replacement therapy and risk of Alzheimer's disease
3. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
4. Risk factors for clinically diagnosed Alzheimer's disease: A case-control study of an Italian population
5. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on ageing
6. A case-control study of Alzheimer's disease in Australia
7. Estrogen replacement therapy and cognitive decline in memory-impaired postmenopausal women
8. Alzheimer's disease: A study of epidemiological aspects
9. A prospective study of estrogen resplacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Ageing
10. 17 Beta-estradiol for postmenopausal estrogen replacement therapy
11. Pharmacokinetic and pharmacologic variation between different estrogen products
12. Cognitive function in nondemented older women who took oestrogen after menopause
13. Estrogen use and verbal memory in healthy postmenopausal women
14. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women
15. Effects of oestrogen on memory function in surgically menopausal women
16. Estrogen replacement therapy and longitudinal decline in visual memory: A possible protective effect?
17. Estrogen replacement therapy in older women: A neuropsychological and brain MRI study
18. Enhanced cognitive performance with estrogen use in nondemented community-dwelling older women
19. Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: Verbal memory changes are associated with the treatment induced estradiol levels
20. Estrogen replacement therapy and cognitive function in older women
21. The effects of hormone replacement therapy, lipoprotein cholesterol levels and other factors on a clock drawing task in older women
22. The effect of short-term estrogen replacement therapy on cognition: A randomized, double-blind, crossover trial in postmenopausal women
23. Estrogen effects on cognition in menopausal women
24. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: A meta-analysis
25. Hormone replacement therapy and reduced cognitive decline in older women: The Cache County Study
26. Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia
27. Higher levels of plasma estradiol and testosterone in healthy elderly men compared with age-matched women may protect aspects of explicit memory
28. Age-related changes in male gonadal function. Implications for therapy
29. Gender, concurrent estrogen use and cognition in AD
30. The Alzheimer's disease Assessment Scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials
31. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: The Kame Project
32. Estrogen replacement therapy and cognitive decline in older community women
33. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease
34. Estrogen use, Apoe and cognitive decline: Evidence of gene-environment interaction
35. Reproductive period and risk of dementia in postmenopausal women
36. Cognitive function and endogenous sex hormones in older women
37. Associations between circulating sex steroid hormones and cognition in normal elderly women
38. Serum estrogen levels, cognitive performance and risk of cognitive decline in older community women
39. Cognitive decline in women in relation to nonprotein-bound oestradiol concentrations
40. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women
41. Methods and results of aromatization studies in vivo
42. Androgen and estrogen dynamics: Relationships with age, weight and menopausal status
43. Changes in circulating steroids with ageing in postmenopausal women
44. Body weight and/or endogenous estradiol as determinants of cortical bone mass and bone loss in healthy early postmenopausal women
45. Weight loss in Alzheimer's disease
46. Weight loss and senile dementia in an institutionalized elderly population
47. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type
48. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type)
49. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type
50. Low-dose estrogen replacement therapy for Alzheimer's disease in women
51. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 Case reports
52. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: A placebo-controlled double-blind study
53. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease
54. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: Results of a placebo-controlled, double-blind, pilot study
55. The role of estrogen in the treatment of Alzheimer's disease
56. High-dose estradiol improves cognition for women with AD: Results of a randomized study
57. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
58. Estrogen replacement therapy for treatment of mild-to-moderate Alzheimer's disease: A 1-year randomized controlled trial
59. Effects of estrogen on cognition, mood and cerebral blood flow in AD: A controlled study
60. The radiologic prediction of Alzheimer's disease: The atropic hippocampal formation
61. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease
62. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
63. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease
64. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease
65. Hippocampal atrophy in normal ageing: An association with recent memory
66. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ε4 allele
67. Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon4 allele
68. Regional cerebral oxygen supply and utilization in dementia: A clinical and physiological study with oxygen-15 and positron tomography
69. Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F] Fluorodeoxyglucose
70. Cortical abnormalities in Alzheimer's disease
71. Positron emission tomography in Alzheimer's disease
72. The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease: A population-based study
73. Cognitive correlates of regional cerebral blood flow in Alzheimer's disease
74. Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease
75. Single-photon emission computed tomography studies of regional cerebral blood flow in multiple infarct dementia
76. Cerebral glucose metabolism in Parkinson's disease with and without dementia
77. (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: A comparison with dementia of the Alzheimer type
78. Preliminary evidence that estrogen protects against age-related hippocampal atrophy
79. Estrogen and cerebral blood flow: A mechanism to explain the impact of estrogen on the incidence and treatment of Alzheimer's disease
80. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women
81. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: A PET study
82. Effect of estrogen on cerebral glucose metabolism in postmenopausal women
83. Effects of estrogen deprivation on brain estrogen and progestin receptor levels and the activation of female sexual behavior
84. Estrogen as a treatment for Alzheimer's disease
85. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance
86. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition
87. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks
88. Modulation of cognition-specific cortical activity by gonadal steroids: A positron-emission tomography study in women
89. Effects of estrogen on patterns of brain activity at rest and during cognitive activity: A review of neuroimaging studies
90. 17-β estradiol protects neurons from oxidative stress-induced cell death in vitro
91. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: A placebo-controlled double-blind study
92. Estrogen regulates metabolism of Alzheimer amyloid β precursor protein
93. Estrogen blocks neurotoxic effects of β-amyloid (1-42) and induces neurite extension on B 103 cells
94. Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen
95. Neuroprotective effects of estrogens: Potential mechanisms of action
96. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood
97. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat
98. Distribution and hormone regulation of oestrogen receptor immunoreactive cells in the hippocampus of male and female rats
99. Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat
100. Estrogens modulate experimentally induced apoptosis of granule cells in the adult hippocampus
101. Estrogen is more than just a 'sex hormone': Novel sites for estrogen action in the hippocampus and cerebral cortex
102. Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats
103. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats
104. Estrogen modulates spontaneous alternation and the cholinergic phenotype in the basal forebrain
105. The estrogen/neurotrophin connection during neural development: Is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant?
106. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats
107. Estrogen and estrogen-progesterone treatments counteract the effect of scopolamine on reinforced T-maze alternation in female rats
108. Estrogen and nerve growth factor-related systems in brain. Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and ageing
109. Effects of gonadal hormone replacement on measures of basal forebrain cholinergic function
110. Cognitive deficits caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey
111. D1 dopamine receptors in prefrontal ortex: Involvement in working memory
112. Regional changes in monoamines in cerebral cortex and subcortical structures of ageing rhesus monkeys
113. Dopamine deficiency in the cerebral cortex in Parkinson's disease
114. Reproductive senescence predicts cognitive decline in aged female monkeys
115. Age-related decline in nigral neuronal function correlate with motor impairments in rhesus monkeys
116. Presynaptic monoaminergic vesicles in Parkinson's disease and normal ageing
117. Ageing produces a specific pattern of striatal dopamine loss: Implications for the aetiology of idiopathic Parkinson's disease
118. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra
119. Parallel loss of presynaptic and postsynaptic dopamine markers in normal ageing
120. Ovarian hormones influence the morphology, distribution and density of tyrosine hydroxylase immunoreactive axons in the dorsolateral prefrontal cortex of adult Rhesus monkeys
121. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: Implications for Parkinson's disease and memory
122. Increased synaptic sprouting in response to oestrogen via an apolipoprotein E-dependent mechanism: Implications for Alzheimer's disease
123. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
124. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain
125. Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells
126. Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis
127. Estrogens influence growth, maturation and amyloid beta-peptide production in neuroblastoma cells and in a beta-APP transfected kidney 293 cell line
128. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein
129. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides